333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2 –negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

ConclusionsThis subgroup analysis from CompLEEment-1 supports the safety and efficacy of RIB + LET in pts with CNS metastasis. Additional patient follow-up is ongoing.Clinical trial identificationNCT02941926.Editorial acknowledgementMedical editorial assistance was provided by Heyuan Sun, PhD, of Healthcare Consultancy Group, LLC, and funded by Novartis Pharmaceuticals Corporation.Legal entity responsible for the studyNovartis.FundingNovartis Pharmaceuticals.DisclosureM. De Laurentiis: Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: Amgen. P. Marchetti: Advisory / Consultancy: Novartis; Advisory / Consultancy: BMS; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Incyte; Advisory / Consultancy: Molteni; Advisory / Consultancy: Roche; Advisory / Consultancy: MSD. F.P. Duhoux: Research grant / Funding (institution): Novartis; Honoraria (institution): Roche; Honoraria (institution): Pfizer; Honoraria (institution): AstraZeneca. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research